Overview

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Christine Mauz-Körholz
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
Euronet Worldwide
Treatments:
Cyclophosphamide
Dacarbazine
Fluorodeoxyglucose F18
Prednisolone
Prednisone
Procarbazine
Vincristine